Company news

Relmada Therapeutics, Inc. news in 2026

Relmada Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London

November 4, 2026

Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026

November 3, 2026

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

September 1, 2026

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

July 28, 2026

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

July 16, 2026

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

June 29, 2026

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

June 11, 2026

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2026

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

May 6, 2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

May 5, 2026

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

March 18, 2026

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

March 12, 2026

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

March 9, 2026

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

March 8, 2026

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

March 8, 2026

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

January 12, 2026

Calls in 2026

Decks in 2026